Vertex Tweaks Data Presentation, Investors React
BioWorld Insight Contributing Writer
For the interim analysis of its Phase II study combining VX-809 and Kalydeco (ivacaftor) in cystic fibrosis patients homozygous for the F508del mutation, Vertex Pharmaceuticals Inc. presented data pooled from the three doses from baseline to day 56 of the trial. The release of the final top-line data for study contained efficacy data for just the largest 600 mg dose of VX-809 with Vertex highlighting the improvement in lung function from day 28 to 56.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST